Selected article for: "detection rate and early isolation"

Author: Liu, Shanshan; Li, Qiuyue; Chu, Xuntao; Zeng, Minxia; Liu, Mingbin; He, Xiaomeng; Zou, Heng; Zheng, Jianghua; Corpe, Christopher; Zhang, Xiaoyan; Xu, Jianqing; Wang, Jin
Title: Monitoring Coronavirus Disease 2019: A Review of Available Diagnostic Tools
  • Cord-id: l1wnp0kl
  • Document date: 2021_6_7
  • ID: l1wnp0kl
    Snippet: Coronavirus disease 2019 (COVID-19) pneumonia is caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has rapidly become a global public health concern. As the new type of betacoronavirus, SARS-CoV-2 can spread across species and between populations and has a greater risk of transmission than other coronaviruses. To control the spread of SARS-CoV-2, it is vital to have a rapid and effective means of diagnosing asymptomatic SARS-CoV-2-positive individuals and patie
    Document: Coronavirus disease 2019 (COVID-19) pneumonia is caused by the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has rapidly become a global public health concern. As the new type of betacoronavirus, SARS-CoV-2 can spread across species and between populations and has a greater risk of transmission than other coronaviruses. To control the spread of SARS-CoV-2, it is vital to have a rapid and effective means of diagnosing asymptomatic SARS-CoV-2-positive individuals and patients with COVID-19, an early isolation protocol for infected individuals, and effective treatments for patients with COVID-19 pneumonia. In this review, we will summarize the novel diagnostic tools that are currently available for coronavirus, including imaging examinations and laboratory medicine by next-generation sequencing (NGS), real-time reverse transcriptase–polymerase chain reaction (rRT-PCR) analysis, immunoassay for COVID-19, cytokine and T cell immunoassays, biochemistry and microbiology laboratory parameters in the blood of the patients with COVID-19, and a field-effect transistor-based biosensor of COVID-19. Specifically, we will discuss the effective detection rate and assay time for the rRT-PCR analysis of SARS-CoV-2 and the sensitivity and specificity of different antibody detection methods, such as colloidal gold and ELISA using specimen sources obtained from the respiratory tract, peripheral serum or plasma, and other bodily fluids. Such diagnostics will help scientists and clinicians develop appropriate strategies to combat COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abnormal level and acute respiratory distress syndrome: 1, 2
    • abnormal level and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • abnormal level and liver damage: 1
    • abnormal level and long covid: 1
    • abnormal level and lung infection: 1
    • abnormal level and lymphocyte count: 1, 2, 3, 4, 5
    • abnormal lymphocyte and absolute lymphocyte count: 1, 2, 3
    • abnormal lymphocyte and acid testing: 1
    • abnormal lymphocyte and acute respiratory distress syndrome: 1, 2, 3
    • abnormal lymphocyte and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
    • abnormal lymphocyte and lung infection: 1
    • abnormal lymphocyte and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • abnormal lymphocyte and lymphocyte count decrease: 1
    • absolute lymphocyte count and acid testing: 1
    • absolute lymphocyte count and active disease: 1
    • absolute lymphocyte count and acute respiratory distress syndrome: 1, 2, 3, 4
    • absolute lymphocyte count and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • absolute lymphocyte count and low sensitivity: 1
    • absolute lymphocyte count and lung infection: 1